ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
19 déc. 2024 17h25 HE
|
ARS Pharmaceuticals, Inc.
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024...
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
18 déc. 2024 08h00 HE
|
ARS Pharmaceuticals, Inc.
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
ARSファーマシューティカルズ (ARS Pharmaceuticals)、neffy®の中国、日本、オーストラリアでの承認申請を発表
13 déc. 2024 16h58 HE
|
ARS Pharmaceuticals, Inc.
サンディエゴ発, Dec. 14, 2024 (GLOBE NEWSWIRE) -- アナフィラキシーに至る可能性のあるアレルギー反応から自身を守るための支援を目指すバイオ医薬品企業であるARSファーマシューティカルズ (ARS Pharmaceuticals, Inc.) (NASDAQ: SPRY)...
ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy®
13 déc. 2024 16h58 HE
|
ARS Pharmaceuticals, Inc.
圣地亚哥, Dec. 14, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) 是一家生物制药公司，致力于帮助高风险患者和护理人员更好地保护患者免于可能导致过敏性休克的过敏反应。该公司今天宣布，其在中国、日本和澳大利亚的授权合作伙伴已在各自国家申请批准 2 毫克剂量的 neffy® （肾上腺素鼻喷雾剂）。 2...
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
12 déc. 2024 14h32 HE
|
ARS Pharmaceuticals, Inc.
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
04 déc. 2024 08h00 HE
|
ARS Pharmaceuticals, Inc.
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of...
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
13 nov. 2024 06h30 HE
|
ARS Pharmaceuticals, Inc.
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive...
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
11 nov. 2024 07h00 HE
|
ARS Pharmaceuticals, Inc.
Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration...
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
06 nov. 2024 08h00 HE
|
ARS Pharmaceuticals, Inc.
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
24 oct. 2024 08h30 HE
|
ARS Pharmaceuticals, Inc.
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...